<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868569</url>
  </required_header>
  <id_info>
    <org_study_id>2009-03</org_study_id>
    <nct_id>NCT00868569</nct_id>
  </id_info>
  <brief_title>Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer</brief_title>
  <official_title>TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether TAC plus FOLFOX4 or TACE plus folfox4 are
      able to improve resection rate and overall survival in patients receiving primary colorectal
      tumor resection than given FOLFOX4 only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We administered three cycles FOLFOX4 plus TAC(oxaliplatin,FUDR and MMC) or FOLFOX4 plus
      TACE(oxaliplatin,FUDR,MMC and embolision) to primary colorectal tumor resected patients with
      unresected liver metastasis. The study endpoints were resection rate of liver metastasis,
      progression-free survival, overall survival as evaluated by intent-to-treat analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years after operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>resection rate of liver metastasis progression-free survival</measure>
    <time_frame>5 years after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Metastasis</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemoembolision (TACE) using oxaliplatin, fudr, mmc and iodine. Then begin folfox4 again.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy (TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE + folfox 4</intervention_name>
    <description>tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml
folfox4</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAC + folfox4</intervention_name>
    <description>tac: oxaliplatin 100mg + fudr 1g + mmc 10mg
folfox4</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &lt; 75 years with histologically proven adenocarcinoma of the colon or rectum

          -  no severe major organ dysfunction

          -  WHO performance status of 0 or 1

          -  no prior cancer therapy

          -  with measurable unresectableliver metastasis

          -  without other metastasis

        Exclusion Criteria:

          -  age &gt;= 75

          -  severe major organ dysfunction

          -  WHO performance status of &gt;1

          -  prior cancer therapy

          -  with other metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianmin xu, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>department of general surgery, zhongshan hospital, fudan university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jianmin xu, MD, PHD</last_name>
    <phone>008613501984869</phone>
    <email>xujmin@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yunshi zhong, MD</last_name>
    <phone>008613564623481</phone>
    <email>zhongamy2002@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianmin xu, MD, PHD</last_name>
      <phone>008613501984869</phone>
      <email>xujmin@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>jianmin xu, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Xujianmin</name_title>
    <organization>Zhongshan hospital, Fudan University</organization>
  </responsible_party>
  <keyword>liver metastasis</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>oxaliplatine</keyword>
  <keyword>transartery chemotherapy</keyword>
  <keyword>embolision</keyword>
  <keyword>Unresectable Liver Metastasis of Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

